All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Randomized Phase 2 Study Of Erdafitinib Versus Investigator Choice Of Intravesical Chemotherapy In Subjects Who Received Bacillus Calmette-Guérin (BCG) And Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) And FGFR Mutations Or Fusions
High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
A Phase 2 Study of CAbozantinib in combination with AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
increase the chances of keeping you cancer free. Researchers will also look at the good and
bad effects of the combination including side effects.